US pharmaceutical and biotechnology company Moderna Inc (NASDAQ:MRNA) has said that deliveries of its COVID-19 vaccine are on track to meet the number of doses previously communicated to governments, Reuters news agency reported on Wednesday.
According to an email sent to Reuters from the company: "Moderna is committed to meeting all quarterly contractual delivery agreements with the European Commission and individual Member States."
Based in Cambridge, Massachusetts, Moderna focuses on drug discovery, drug development and vaccine technologies based on messenger RNA (mRNA).
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses